261 related articles for article (PubMed ID: 21979862)
1. Emerging techniques to treat corneal neovascularisation.
Menzel-Severing J
Eye (Lond); 2012 Jan; 26(1):2-12. PubMed ID: 21979862
[TBL] [Abstract][Full Text] [Related]
2. Corneal neovascularization: an anti-VEGF therapy review.
Chang JH; Garg NK; Lunde E; Han KY; Jain S; Azar DT
Surv Ophthalmol; 2012 Sep; 57(5):415-29. PubMed ID: 22898649
[TBL] [Abstract][Full Text] [Related]
3. Serum eyedrops antagonize the anti(lymph)angiogenic effects of bevacizumab in vitro and in vivo.
Hos D; Koch KR; Bucher F; Bock F; Cursiefen C; Heindl LM
Invest Ophthalmol Vis Sci; 2013 Sep; 54(9):6133-42. PubMed ID: 23970469
[TBL] [Abstract][Full Text] [Related]
4. Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis.
Chen WL; Lin CT; Lin NT; Tu IH; Li JW; Chow LP; Liu KR; Hu FR
Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1659-65. PubMed ID: 18997093
[TBL] [Abstract][Full Text] [Related]
5. [Vascular morphological and microdensity changes of corneal neovascularization induced by topical bevacizumab and sunitinib in an animal model].
Pérez-Santonja JJ; Campos-Mollo E; Lledó-Riquelme M; Fernández-Sánchez L; Cuenca-Navarro N
Arch Soc Esp Oftalmol; 2013 Dec; 88(12):473-81. PubMed ID: 24257257
[TBL] [Abstract][Full Text] [Related]
6. Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization.
Koenig Y; Bock F; Horn F; Kruse F; Straub K; Cursiefen C
Graefes Arch Clin Exp Ophthalmol; 2009 Oct; 247(10):1375-82. PubMed ID: 19415316
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin).
Manzano RP; Peyman GA; Khan P; Carvounis PE; Kivilcim M; Ren M; Lake JC; Chévez-Barrios P
Br J Ophthalmol; 2007 Jun; 91(6):804-7. PubMed ID: 17179168
[TBL] [Abstract][Full Text] [Related]
8. The effect of bevacizumab on corneal neovascularization in rabbits.
Kim WJ; Jeong HO; Chung SK
Korean J Ophthalmol; 2010 Aug; 24(4):230-6. PubMed ID: 20714387
[TBL] [Abstract][Full Text] [Related]
9. Effects of subconjunctival tocilizumab versus bevacizumab in treatment of corneal neovascularization in rabbits.
Yoo AR; Chung SK
Cornea; 2014 Oct; 33(10):1088-94. PubMed ID: 25119962
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).
Kim TI; Kim SW; Kim S; Kim T; Kim EK
Cornea; 2008 Apr; 27(3):349-52. PubMed ID: 18362666
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Subconjunctival Injection of Bevacizumab in Regressing Corneal Neovascularisation.
Shah SSA
J Coll Physicians Surg Pak; 2019 May; 29(5):430-434. PubMed ID: 31036112
[TBL] [Abstract][Full Text] [Related]
12. Isoliquiritigenin from licorice root suppressed neovascularisation in experimental ocular angiogenesis models.
Jhanji V; Liu H; Law K; Lee VY; Huang SF; Pang CP; Yam GH
Br J Ophthalmol; 2011 Sep; 95(9):1309-15. PubMed ID: 21719569
[TBL] [Abstract][Full Text] [Related]
13. Topical bevacizumab therapy for corneal neovascularization.
DeStafeno JJ; Kim T
Arch Ophthalmol; 2007 Jun; 125(6):834-6. PubMed ID: 17562998
[No Abstract] [Full Text] [Related]
14. Doxycycline enhances the inhibitory effects of bevacizumab on corneal neovascularization and prevents its side effects.
Su W; Li Z; Li Y; Lin M; Yao L; Liu Y; He Z; Wu C; Liang D
Invest Ophthalmol Vis Sci; 2011 Nov; 52(12):9108-15. PubMed ID: 22039247
[TBL] [Abstract][Full Text] [Related]
15. Recent drug therapies for corneal neovascularization.
Liu X; Wang S; Wang X; Liang J; Zhang Y
Chem Biol Drug Des; 2017 Nov; 90(5):653-664. PubMed ID: 28489275
[TBL] [Abstract][Full Text] [Related]
16. The impact of subconjuctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model.
Sener E; Yuksel N; Yildiz DK; Yilmaz B; Ozdemir O; Caglar Y; Degirmenci E
Curr Eye Res; 2011 Nov; 36(11):1005-13. PubMed ID: 21999227
[TBL] [Abstract][Full Text] [Related]
17. [Experimental and morphological study of the effect of antiangiogenic therapy on corneal neovessels].
Mamikonian VR; Voevodina TM; Fedorov AA; Budzinskaia MV; Balaian ML
Vestn Oftalmol; 2013; 129(6):45-50. PubMed ID: 24624802
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor inhibitors for treatment of corneal neovascularization: a meta-analysis.
Papathanassiou M; Theodoropoulou S; Analitis A; Tzonou A; Theodossiadis PG
Cornea; 2013 Apr; 32(4):435-44. PubMed ID: 22668582
[TBL] [Abstract][Full Text] [Related]
19. Effect of bevacizumab on corneal neovascularization in experimental rabbit model.
Ahmed A; Berati H; Nalan A; Aylin S
Clin Exp Ophthalmol; 2009 Sep; 37(7):730-6. PubMed ID: 19788671
[TBL] [Abstract][Full Text] [Related]
20. The effect of subconjuctival combined treatment of bevacizumab and triamcinolone acetonide on corneal neovascularization in rabbits.
Kang S; Chung SK
Cornea; 2010 Feb; 29(2):192-6. PubMed ID: 20098156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
